<DOC>
	<DOCNO>NCT01007630</DOCNO>
	<brief_summary>A decrease loss sense smell common patient Parkinson 's Disease even early stage disease . There treatment proven improve sense smell patient Parkinson 's Disease . Rasagiline ( brand name : Azilect ) approve U.S. Food Drug Administration ( FDA ) May 16th 2006 use Parkinson 's patient treat motor symptom associate disease . The purpose study see change sense smell start Rasagiline .</brief_summary>
	<brief_title>A Study Assessing Change Sense Smell After Rasagiline Use Parkinson 's Patients</brief_title>
	<detailed_description>This study last approximately 10 week . - 2 visit The Parkinson 's Institute Sunnyvale , California - 1 phone call visit You ask take either Rasagiline ( Azilect ) placebo ( identical pill without active ingredient ) - 5 6 chance receive Rasagiline ( Azilect ) - 1 6 chance receive placebo - Neither study team know assign - This information available case emergency To eligible study , must : - 90 year old young - decreased loss smell complete loss smell - take Selegiline Rasagiline within past 12 month - smoke within last year - stable dose Parkinson 's medication ( PD medicine ) - history head trauma , nasal surgery , nasal inflammation cause congestion polyp , nasal/sinus infection , prior Zicam use - used decongestant , antihistamine inhale steroid within 2 week study willing avoid treatment study</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Men woman Parkinson 's Disease ( PD ) , define presence least two cardinal sign PD ( bradykinesia , rest tremor , rigidity ) without identifiable cause parkinsonism sign atypical parkinsonism Functional hyposmia anosmia , define UPSIT score less 25th percentile age gendermatched norm Have stable dose PD medication least 30 day Age &lt; = 90 year Willing able give inform consent Women childbearing potential may participate provide willing use adequate contraceptive method duration study . Women childbearing potential must negative pregnancy test screen visit nonlactating . Prior use MAO inhibitor , include selegiline rasagiline within last 12 month Presence condition investigator 's opinion may significantly cause olfactory impairment , include prior head trauma , nasal surgery , nasal inflammation cause concurrent congestion polyp , nasal sinus infection , prior intranasal zinc salt ( Zicam ) use , history smoking within past year Presence dementia significant cognitive impairment MiniMental State Examination ( MMSE ) &lt; 24 Present medical surgical condition opinion investigator would preclude participation completion study procedure Use experimental medication within 60 day baseline Use decongestant , antihistamine , inhaled steroid within 2 week baseline Use medication contraindicate use rasagiline ( Investigator take consideration concomitant antidepressant use per prescribe information guideline rasagiline )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Parkinson 's</keyword>
	<keyword>Parkinsons</keyword>
	<keyword>Parkinson</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>PD</keyword>
	<keyword>Rasagiline</keyword>
	<keyword>Azilect</keyword>
	<keyword>Olfactory</keyword>
	<keyword>Sense Smell</keyword>
	<keyword>UPSIT</keyword>
</DOC>